TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00439244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days.
Study: NCT01018251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/computed tomography

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLT-PET/CT
Study: NCT03731169

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Voriconazole genotype-specific dosing
Description: Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
Study: NCT00789659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative pressure dressing
Description: A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
Study: NCT01331798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohera TissuGlu Surgical Adhesive
Description: TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control- Standard of care
Description: Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
Study: NCT00488176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetirizine
Description: cetirizine
Study: NCT00205374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cidofovir
Description: With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
Study: NCT00488176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast and cetirizine
Description: montelukast and cetirizine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02325375

Intervention type: PROCEDURE
Intervention: lumbar puncture for spinal fluid and blood sample
Description: lumbar puncture for spinal fluid and blood sample

Intervention type: PROCEDURE
Intervention: lumbar puncture for spinal fluid and blood sample
Description: lumbar puncture for spinal fluid and blood sample

Intervention type: PROCEDURE
Intervention: lumbar puncture for spinal fluid and blood sample
Description: lumbar puncture for spinal fluid and blood sample
Study: NCT01385553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers for Change
Description: FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Drug Counseling
Description: Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
Study: NCT03534557

Intervention type: DIAGNOSTIC_TEST
Intervention: FEV6 spirometry
Description: During the same spirometry, to compare the relative value of FVC and FEV6
Study: NCT03057431

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Once daily for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg hydrochlorothiazide
Description: Once daily for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25.0 mg hydrochlorothiazide
Description: Once daily for 3 years
Study: NCT02665845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ASA
Description: 5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids will be given to all patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids will be given to all patients.
Study: NCT03996629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education and compliance
Description: When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
Study: NCT01990482

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffe

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffe

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study: NCT02191761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04755
Description: Escalating Doses
Study: NCT03680638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apocynin
Description: This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
Study: NCT04075591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iDesign Refractive Studio with STAR S4 IR® Excimer laser System
Description: Surgeons will perform wavefront-guided monovision LASIK for the treatment of myopic subjects with presbyopia based upon measurements obtained with an iDesign Refractive Studio.
Study: NCT00776750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent split influenza vaccine
Description: standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
Study: NCT00763061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% Ophthalmic Solution (Travatan)
Description: Travoprost at 9 AM + Placebo \& 9 PM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5% Ophthalmic Solution (Timoptic)
Description: Timolol in each eye, twice daily at 9 AM \& 9 PM
Study: NCT02024113

Intervention type: OTHER
Intervention: Venous blood sample
Description: Collection of a venous blood sample to investigate metabolic changes in blood

Intervention type: OTHER
Intervention: Venous blood sample
Description: Collection of a venous blood sample to investigate metabolic changes in blood
Study: NCT01839318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A contact lenses
Study: NCT03783442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match Tislelizumab
Study: NCT03393936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCT301-38
Description: Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCT301-59
Description: Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
Study: NCT03057431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50.0 mg hydrochlorothiazide
Description: Once daily for 3 years
Study: NCT04074460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General Anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoflurane, sevoflurane or desflurane
Description: General Anaesthesia
Study: NCT04507828

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Treatment Planning using the DIBH Technique
Description: Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours. The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan. Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
Study: NCT02209558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Sternal Precautions
Description: Visual depiction of SPs in addition to standard of care written precautions
Study: NCT02265536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: Administered IV
Study: NCT03574766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Daily meditation
Study: NCT00349349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Intravenous infusion
Study: NCT00706108

Intervention type: BEHAVIORAL
Intervention: Observational study
Description: Observational (descriptive) study of technical and non-technical performance
Study: NCT02566187

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Atorvastatin Combination Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Atorvastatin Combination Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Study: NCT01925040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of restoration
Description: Placement of restorations

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of restoration
Description: Placement of restorations
Study: NCT04645316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: In the sevoflurane group (n = 25), after the induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, the Sevoflurane concentration will be adjusted between 1-2%, the BIS value will be 40-60, and it will be inhaled with an air / O2 mixture to be FiO2: 0.4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: In the desflurane group (n = 25), after induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, Desflurane concentration will be adjusted between 6-8%, BIS value will be 40-60 and it will be inhaled with a mixture of air / O2 mixture to be FiO2: 0.4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: In the propofol-remifentanyl group (n = 25), rocuronium 0.6 mg / kg will be administered for intubation after 2 mg / kg propofol and 1 µg / kg remifentanil. Maintenance of anesthesia will be adjusted to be between 10 mg / kg / h for the first 10 minutes, 8 mg / kg / h for the following 10 minutes, and then by 6 mg / kg / h propofol infusion, with the BIS value between 40-60. Patients in this group will be inhaled with a mixture of air / O2 to be FiO2: 0.4. Inhalation anesthetics will not be used in this group.
Study: NCT00144040

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physician & patient education on appropriate antibiotic use

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rapid C-reactive protein testing to guide antibiotic treatment
Study: NCT03213145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraconazole
Description: Subjects will receive itraconazole once daily from Day 5 through Day18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects will receive rifampin once daily from Day 5 through Day 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305
Description: Subjects will receive EDP 305 once daily on Day 1 and Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305
Description: Subjects will receive EDP 305 once daily on Day 1 and Day 14
Study: NCT03380494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overhead perturbation training
Description: A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-perturbed training
Description: A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
Study: NCT02973594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03486769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M1 stimulation
Description: stimulating primary motor cortex with anodal transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M1 stimulation
Description: stimulating primary motor cortex with anodal transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M1 stimulation
Description: stimulating primary motor cortex with anodal transcranial direct current stimulation
Study: NCT01510236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help program
Description: The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help program
Description: The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
Study: NCT01718600

Intervention type: BEHAVIORAL
Intervention: Neuropsychological testing
Study: NCT03158805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIRAGLUTIDE
Description: 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study: NCT05427305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB008
Description: 15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death